Haque, A. A. (2026). AN IN-SILICO APPROACH TO REPURPOSE FDA-APPROVED PROPRANOLOL AGAINST PD-L1 PROTEIN TARGET IN CANCER TREATMENT. BME DEPT. MIST.
Ondo kopiatu da
Kopiatzeak huts egin du
Chicago Style (17th ed.) Zitazioa
Haque, AKM Arefen. AN IN-SILICO APPROACH TO REPURPOSE FDA-APPROVED PROPRANOLOL AGAINST PD-L1 PROTEIN TARGET IN CANCER TREATMENT. Dhaka: BME DEPT. MIST, 2026.
Ondo kopiatu da
Kopiatzeak huts egin du
MLA (9th ed.) Zitazioa
Haque, AKM Arefen. AN IN-SILICO APPROACH TO REPURPOSE FDA-APPROVED PROPRANOLOL AGAINST PD-L1 PROTEIN TARGET IN CANCER TREATMENT. BME DEPT. MIST, 2026.
Ondo kopiatu da
Kopiatzeak huts egin du
Kontuz: berrikusi erreferentzia hauek erabili aurretik.